China Tracker - Details for Biostar Pharmaceuticals (BSPM)

 Biostar Pharmaceuticals
Shares Outstanding (MRQ): 9.40 mill
New Shares / Dilution (TTM): 0.14 mill1.50%
Cash (MRQ): 18.71 mill109.36%
Account Receivables (MRQ): 23.58 mill137.84%
Account Receivables (Q/Q): -10.89 mill-31.59%
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): -48.68% 
Revenue Growth (Y/Y): -68.51%
Net Income Growth (Q/Q): -172.81% 
Net Income Growth (Y/Y): -138.00%
EPS Growth (Y/Y): -137.44%
Net Margin (Q/Q): -19.3% (13.6%)-33.00% 
Net Margin (Y/Y): -19.3% (16.0%)-35.40% 
EPS | P/E (2 MRQ Projection): $0.1314.51
CFPS | P/CF (2 MRQ Projection): $0.583.14
Price/Sales (2 MRQ Projection): 0.36
Price/Book (MRQ): 0.25
Auditor: Mazars CPA 
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2012-10-07): $0.355.20
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Direct Offering on 2007-11-01 
Uplisting to Senior Exchange: on 2010-04-23 at $14.04 (-87.04% since Uplisting)

 Business Outlook

The Company is reiterating its fiscal 2011 full year net sales guidance of 20-25% growth and aims to further penetrate in rural area by establishing 3,000 additional rural sales outlets and take total number of rural sales outlets to 13,000 from 10,000 last year.

(Source: PR Newswire, 2011-08-15)

We are optimistic about 2011 and the ability to sell through all of our products through a robust distribution channel and rural sales network. We are confident in meeting our target for the year of 20-25% growth in revenues year-over-year.

(Source: PR Newswire, 2011-05-16)

"We implemented a broader marketing strategy for our flagship Xin Aoxing Capsule, complemented by our expansion into more retail locations in rural areas. This enabled us to achieve record sales and earnings for the year. We expect to have 13,000 rural locations by the end of 2011, up from approximately 10,000 at the end of 2010, and believe this sales channel will further drive incremental growth for the year."

Biostar launched 5 new products during 2010, including health products such as Tangning Capsule, Yizi Capsule, Shengjing Capsule and Aoxing Ointment. Total revenue from new products was approximately $6.7 million during 2010, a 30% increase and further increases are anticipated during 2011. The Company expects to receive final SFDA approval to produce Zushima Analgesic spray, a pain reliever product intended for use by military personnel during the first half of 2011. Management expects total sales from new products to represent 10% of its forecast for 2011.

(Source: PR Newswire, 2011-03-25)

    see all Business Outlook notes

 Analyst Coverage (show more)
2011-05-16Rodman & RenshawReiterationOutperform$7.00
2011-03-25Rodman & RenshawReiterationOutperform$7.00
2010-12-13Rodman & RenshawReiterationOutperform$7.00
2010-11-18Rodman & RenshawInitiationOutperform$7.00
2010-02-16EquityNet ResearchInitiationStrong Buy$9.13

BSPM is currently followed by 2 analysts. Both give the stock a positive rating. The average price target is 8.07, which implies 343.13% upside from current price.


 Investor Presentations
2011-07-18 (HTML)   VIEW
2011-02-18 (HTML)   VIEW
2010-09-13 (HTML)   VIEW
2010-03-09 (HTML)   VIEW
BSPM
Healthcare & Drugs
SCORE
7
READ: Score Cards Explained
SAFETY/RISK SCORE
EXTREME RISK
DETAILS: Safety/Risk Model for BSPM
Current Price:  $1.82
F10k Day (2009-08-14): -84.84%$12.00
2009 Close: -86.37%$13.35
2010 Close: -78.49%$8.46
2011 Close: -2.16%$1.86
High (2012-04-23): -13.75%$2.11
Low (2012-04-03): 224.99%$0.56
Exchange: NCM
Market Capitalization: 17.11 mill
Total Shares: 9.40 mill
Float: 2,220,000.00 mill
Avg Volume: 153.20 k
Short Interest: 47.90 k
Short Ratio: 0.08%0.3 d
Last Quarter: 2012-06-30
Revenue (MRQ): 8.16 mill
Net Income (MRQ): -1.58 mill
Op. Cash Flow (MRQ): -3.02 mill
all financial data provided without warranty